Artikkel

Building an international pricing architecture for emerging biopharma

  • Rafael de Alencar, MSc

How emerging companies can expand patient access, realize the value of innovation and protect long-term strategic flexibility
International pricing decisions are becoming more connected. Reference pricing, visible prices, contracting precedents and health technology assessment (HTA) outcomes already transmit value signals across markets. The US Most Favored Nation (MFN) policy direction strengthens that link through GENEROUS in Medicaid and the proposed GUARD and GLOBE models in Medicare, which use international prices to inform US drug economics.

This puts the US firmly in the international pricing environment and raises important questions for emerging biopharmaceutical companies as to how they can and should plan their launch strategies. 

The challenge for these companies will be how to broaden patient access and realize incremental value without risking unintended global consequences from pricing policies.

Different starting points, one architectural challenge

Emerging biopharmaceutical companies may originate in any market. However, the most common case is a US company that is expanding into Europe, Japan, Canada, Australia and selected emerging markets. It must translate a US commercial and evidence foundation into systems where HTA, public budgets and affordability constraints shape price and access.

On the other hand, a European biotech, while likely more familiar with the multi-country HTA environment than its US counterpart, may choose to launch first in the US to avoid dealing with fragmented national pricing and reimbursement requirements at launch. Its challenge is to balance US price potential while maintaining a wider global ambition.

A China-originating biotech, meanwhile, may expand through licensing, partnership, a NewCo (New Company) or selective direct commercialization. It must determine whether its evidence and value proposition will travel credibly and who will control pricing and access once regional rights are transferred.

The origin market changes the launch strategy, not the underlying need, which should always be to translate the assets value proposition into a coherent international system before individual commitments narrow future choices. The challenge for companies, regardless of their origin, is to establish an integrated view around where access should be prioritized, what evidence payers will require, how much price dispersion is acceptable and which local decisions could constrain their asset elsewhere.

Securing a successful price in the first market does not mean an emerging biopharma company has an international pricing strategy. As they consider how to manage the complex intersection between sustainable access and a coherent pricing and economic strategy, they will need to define the best approach. This article explores three design choices to consider as these emerging companies navigate different launch strategies.
A product’s potential launch value should be built on a market assessment, which will establish what value the asset can credibly support and what role each market should play. This assessment will depend on 1) unmet need; 2) clinical differentiation; 3) the eligible population; 4) economic and system value (for example, could the product reduce resource use or treatment burden); 5) strength of the evidence; and 6) affordability based on population uptake and duration. 

These considerations help to establish a set of value hypotheses explaining potential support for differentiated pricing and access, and under which assumptions. Each market can then be assessed across patient and access opportunity, value and commercial potential, cross-market exposure, and evidence and execution feasibility. This supports six market roles:

  • Value-establishing supports the intended global position and creates a credible payer precedent.
  • Access-priority addresses significant patient needs under sustainable conditions.
  • Growth: offers meaningful patient and commercial potential with manageable exposure
  • Reference-sensitive: requires closer control because outcomes may affect other countries
  • Selective entry: proceeds only if defined evidence, pricing, access or operating conditions are met.
  • Deferred or alternative access warrants later entry or a different pathway while material conditions remain unresolved.

A market role must change the decision by guiding evidence, access to breadth, pricing parameters, contracting flexibility, timing, and governance. An access-priority market with constrained economics, for example, could prompt restricted eligibility, staged entry or an alternative route rather than a binary launch decision.

Market roles should then be translated into a sequencing roadmap that balances time to reimbursed access, value-establishing potential, evidence of readiness, expected price and access conditions, cross-market exposure and execution feasibility.

Companies can start by testing a small number of scenarios, such as earlier access and cash generation; waiting for stronger evidence or favorable precedents; or deferring reference-sensitive markets until key uncertainties are resolved. The roadmap should assign each market to a launch wave, define entry conditions, and identify triggers that could change timing.
A price ambition is credible only if the evidence can support it in the intended markets. If the payer perspective is introduced too late in the clinical development cycle, comparator selection, endpoints and population definitions may be difficult to change, leaving pricing teams to defend a value proposition the evidence was not designed to demonstrate.

The need for earlier evidence planning has become more apparent with the EU Joint Clinical Assessment (JCA). The JCA began in 2025 for new oncology medicines and advanced therapies, expands to orphan medicines in 2028 and to other in-scope medicines in 2030. It creates a shared clinical assessment, but pricing, reimbursement and economic decisions remain national. Market-specific evidence and access planning therefore remain essential.

A practical evidence architecture has three layers:

  • Shared global evidence: disease burden, population, clinical outcomes, safety, patient-reported outcomes, treatment-pathway effects, resource use, durability and differentiation.
  • Market-specific adaptation: local comparators, standard of care, relative-effectiveness methods, cost-effectiveness, budget impact, epidemiology, subgroups and local data requirements.<
  • Lifecycle evidence and reassessment: longer follow-up, real-world outcomes, utilization, subgroup effectiveness, durability, new indications and contractual evidence needs.

Evidence readiness in each market ranges from prepared to adaptable to at risk and to unresolvable before launch. Leadership should decide whether remaining uncertainty can be managed through positioning, access conditions, post-launch evidence or delay.

The practical output is an evidence-to-value matrix linking each value driver to available evidence, market relevance, gaps, pricing or access consequences, mitigation, owner and milestone.

The strategic question is not only “What price could this evidence support?” It is “What evidence does the intended architecture require, and which choices remain possible with the evidence available?
Every global ambition needs to be converted into country guidance. Country teams and partners need clarity on evidence assumptions, intended access outcome, concession boundaries and potential consequences elsewhere.

A useful country decision corridor contains five connected elements: price (for example, target range); access (including target population, restrictions, etc.); contracting conditions (such as potential concessions and expected return); safeguards (for example reference pricing risk across the lifecycle); and escalation, which includes any circumstance that requires broader review because a proposal sits outside the pricing corridor or changes a global assumption.

All these elements should be weighed against eligibility, earlier and predictable access, and improved affordability, while being ready to escalate where required, such as any unsustainable price falls or restrictions that materially change the eligible population. 

The corridor does not override local payer realities; it defines where adaptation is expected, where review is required and where the wider strategy may be at risk.

Conclusion: Execute the strategy while preserving flexibility

Emerging companies do not need big-pharma infrastructure, but they do need clear oversight and objectives before negotiations can begin.

Whether the company builds locally, works through a partner or licenses regional rights, the pricing architecture must travel with the asset. Agreements should clarify ownership, approval rights, information-sharing and escalation.

At a minimum, viable governance requires a small cross-functional pricing council, explicit global and local decision rights, standard country decision cards, approval thresholds, exception processes and scheduled reviews. 

Flexibility is also key and changing conditions will require a careful review of the pricing architecture. New clinical data, regulatory or HTA outcomes, contracting precedents, competition, policy change, population expansion and partnering events may require reassessment. 

The strategic imperative is to agree on what must remain coherent globally, where local adaptation creates value and what developments require the architecture to change. For emerging biopharma leaders, that means being able to explain what the pricing architecture achieves locally and what it commits the company to globally.

Ansvarsfraskrivelse:
Informasjonen i denne artikkelen er ment å informere leserne om et emne relatert til Cencoras evner og er ikke juridisk eller kjøpsrådgivning. Cencora, Inc. oppfordrer leserne til å gjennomgå de siterte referansene i denne artikkelen og bruke sin egen kunnskap og erfaring når de tar beslutninger.
 

 

Vi er her for å hjelpe deg

Ta kontakt med teamet vårt i dag for å lære mer om hvordan Cencora bidrar til å skape fremtidens helsevesen.

Related solutions

Globalt nettverk for markedstilgang
Vårt ledende team av verdieksperter forvandler dokumentasjon, innsikt i retningslinjer og markedsinformasjon til effektive globale strategier for markedstilgang, som hjelper kunder med å effektivt navigere dagens komplekse landskap innen helsevesenet.
  • Kommersialiseringsstøtte
  • Farmasøytiske produsenter
  • USA
Rådgivning innen folkehelse (PHE)
Folkehelse (PHE) blir en del av Cencoras globale konsulenttjenester
  • Støtte for legemiddelforskning og klinisk utvikling
  • Kommersialiseringsstøtte
  • Støtte for pasienttilgang og etterlevelse
  • Farmasøytiske produsenter
  • Globalt
Pasienttilgang og rimelighet
Hjelp henviste spesialitets- og infusjonspasienter med å nå dekket behandling ved å fjerne tilgangsbarrierer.
  • Apotekløsninger
  • Løsninger for tjenesteleverandører
  • Helsevesen
  • USA

Relaterte ressurser

Rapport

Utsikter for markedstilgang: 2027-trender i et uforutsigbart klima

References
1. Centers for Medicare & Medicaid Services. GENEROUS Model.
2. EFPIA. Patients in Europe wait longer for new medicines as inequality grows between Member States. May 19, 2026.
3. European Medicines Agency. Health technology assessment bodies.
4. European Commission. Joint Clinical Assessments.
5. EMA. Joint HTAb-regulatory perspectives on evidence challenges and uncertainties. April 1, 2025.
6. PMDA / MHLW Japan. The Background and Content of the Notification. August 4, 2025.
7. Cencora. Understanding international reference pricing: The global impact of a single price decision.
8. Cencora. How MFN policy and IRP reshape global market access.
9. White House. Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Executive Order 14297. May 12, 2025.
10. Centers for Medicare & Medicaid Services. GUARD Model.
11. Centers for Medicare & Medicaid Services. GLOBE Model.
12. European Commission. Scientific specifications of medicinal products subject to joint clinical assessments. June 2024.